

Clinical Trial	CKD-EPI CT Collaborators	Study request path for future researchers
AASK ¹	Tom Greene	NIDDK Central Repository
ABCD ²	Raymond O. Estacio, Rebecca Hanratty	Write to corresponding author
ACCOMPLIS H ³	Data received from Novartis via the Clinical Study Data Request (CSDR) platform	CSDR data sharing platform
ADVANCE ⁴	Mark Woodward, John Chalmers	Write to corresponding author
ALTITUDE ⁵	Hiddo JL Heerspink, Hans-Henry Parving	Write to corresponding author
Appel ⁶	Gerald B. Appel, Pietro Canetta	Write to corresponding author
Brenner ⁷	Barry M Brenner	Write to corresponding author
CanPREVENT ⁸	Brendan Barrett	Write to corresponding author
CANVAS ⁹	Bruce Neal, Vlado Perkovic, Kenneth W Mahaffey, Brendon Neuen	Vivli data sharing platform
CARMELINA ¹⁰	Data received from Boehringer Ingelheim	Write to corresponding author
CAROLINA ¹¹	Data received from Boehringer Ingelheim	Write to corresponding author
CHARM-Added ¹²	Data received from AstraZeneca	Write to corresponding author
CKD- FIX ¹³	Sunil Badve, David Johnson	Write to corresponding author
CREDENCE ¹⁴	Vlado Perkovic, Kenneth W Mahaffey, Meg Jardine, Brendon Neuen	Vivli data sharing platform
DAPA-CKD ¹⁵	Data received from AstraZeneca	Write to corresponding author
Donadio 1999 ¹⁶ , 2001 ¹⁷	Fernando Fervenza	Write to corresponding author
EMPA-REG OUTCOME ¹⁸	Christoph Wanner, Maximilian von Eynatten	Write to corresponding author
EXAMINE ¹⁹	Data received from GlaxoSmithKline via the Vivli platform	Vivli
FIDELIO-DKD ²⁰	Data received from Bayer	Write to corresponding author
FSGS/FONT ²¹	Data received from NIDDK	NIDDK Central Repository
Goicoechea ²²	Marian Goicoechea, Eduardo Verde, Ursula Verdalles, David Arroyo	Write to corresponding author
HALT-PKD A ²³	Ronald D. Perrone, Arlene Chapman , Vicente Torres , Alan Yu , Godela Brosnahan	NIDDK Central Repository
HALT-PKD B ²⁴	Ronald D. Perrone, Arlene Chapman , Vicente Torres , Alan Yu , Godela Brosnahan	NIDDK Central Repository
Hannedouche ²⁵	Thierry Hannedouche	Write to corresponding author
Harmony Outcomes ²⁶	Data received from Takeda via the Vivli platform	Vivli
HKVIN ²⁷	Philip Kam-Tao Li, Kai-Ming Chow, Cheuk-Chun Szeto, Chi-Bon Leung	Write to corresponding author
Hou ²⁸	Di Xie, Fan Fan Hou	Write to corresponding author
IDNT ²⁹	Julia B. Lewis, Jamie Dwyer, Marc Pohl, Itamar Raz, Lawrence Hunsicker	Write to corresponding author
Ihle/Kincaid ³⁰	Gavin J. Becker, Benno U. Ihle, Priscilla S. Kincaid-Smith	Write to corresponding author
Kamper	Annalise Kamper	Write to corresponding author
Katafuchi ³¹	Ritsuko Katafuchi	Write to corresponding author
LEADER ³²	Data received from Novo Nordisk A/S	Send request on company portal
Lewis 1992 ³³ , 1993 ³⁴	Julia B. Lewis	Write to corresponding author

Maes ³⁵	Bart D. Maes, An Vanacker, Thomas Malfait	Write to corresponding author
Maschio/ AIPRI ³⁶	Tazeen H Jafar, Giuseppe Maschio, Francesco Locatelli	Write to corresponding author
MASTERPLAN ³⁷	Jan van den Brand, Jack FM Wetzels, Peter Blankestijn, Arjan van Zuilen	Write to corresponding author
MDRD Study A ³⁸	Tom Greene	NIDDK Central Repository
MDRD Study B ³⁸	Tom Greene	NIDDK Central Repository
ORIENT ³⁹	Enyu Imai, Fumiaki Kobayashi, Hirofumi Makino, Juliana C.N. Chan	Write to corresponding author
PARADIGM-HF ⁴⁰	Data received from Novartis via the Clinical Study Data Request platform	Clinical Study Data Request
PEGASUS ⁴¹	Data received from AstraZeneca	Write to corresponding author
PLATO ⁴²	Data received from AstraZeneca	Write to corresponding author
Ponticelli 1989 ⁴³ , 1992 ⁴⁴ , 1998 ⁴⁵ , 2006 ⁴⁶	Patrizia Passerini	Write to corresponding author
Pozzi 2004 ⁴⁷ , 2010 ⁴⁸ , 2013 ⁴⁹	Lucia Del Vecchio, Francesco Locatelli, Simeone Andrulli, Claudio Pozzi, Donatella Casartelli	Write to corresponding author
Praga 2003 ⁵⁰	Manuel Praga, Hernando Trujillo, Teresa Caverro, Angel Sevillano	Write to corresponding author
REIN-1 ⁵¹ and 2 ⁵²	Piero Ruggenenti, Annalisa Perna, Fabiola Carrara, Giulia Gherardi	Write to corresponding author
RENAAL ⁵³	Hiddo JL Heerspink, William F Keane	Write to corresponding author
ROAD ⁵⁴	Di Xie, Fan Fan Hou	Write to corresponding author
Schena ⁵⁵	Francesco P. Schena, Carlo Manno	Write to corresponding author
SHARP ⁵⁶	Richard Haynes, William G. Herrington, Colin Baigent, Martin Landray	Write to corresponding author
SONAR ⁵⁷	Hiddo JL Heerspink	Write to corresponding author
SPRINT ⁵⁸	Data received from the NHLBI Biologic Specimen and Data Repository Information Coordinating Center	NHLBI BioLINCC
STOP-IgAN ⁵⁹	Jürgen Floege, Thomas Rauen, Claudia Seikrit, Stefanie Wied	Write to corresponding author
SUN-MACRO ⁶⁰	Julia B. Lewis	Write to corresponding author
TOPCAT ⁶¹	Data received from the NHLBI Biologic Specimen and Data Repository Information Coordinating Center	NHLBI BioLINCC
Toto ⁷	Robert D. Toto	Write to corresponding author
Van Essen ⁶²	Dick de Zeeuw, Paul E. de Jong	Write to corresponding author
Zucchelli ⁶³	Tazeen H Jafar, Mauro Saddelli, Pietro Zucchelli	Write to corresponding author

References

1. Wright JT, Jr., Bakris G, Greene T, et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. *JAMA*. Nov 20 2002;288(19):2421-31. doi:joc20772 [pii]
2. Estacio RO, Jeffers BW, Gifford N, Schrier RW. Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes. *Diabetes care*. Apr 2000;23 Suppl 2:B54-64.
3. Jamerson K, Weber MA, Bakris GL, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. *The New England journal of medicine*. Dec 4 2008;359(23):2417-28. doi:10.1056/NEJMoa0806182
4. Patel A, MacMahon S, Chalmers J, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. *New England Journal Medicine*. Jun 12 2008;358(24):2560-72. doi:10.1056/NEJMoa0802987

5. Parving HH, Brenner BM, McMurray JJ, et al. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. *The New England journal of medicine*. Dec 06 2012;367(23):2204-13. doi:10.1056/NEJMoa1208799
6. Frisch G, Lin J, Rosenstock J, et al. Mycophenolate mofetil (MMF) vs placebo in patients with moderately advanced IgA nephropathy: a double-blind randomized controlled trial. *Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association*. Oct 2005;20(10):2139-45.
7. Jafar TH, Stark PC, Schmid CH, et al. Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis. *Annals of internal medicine*. Aug 19 2003;139(4):244-52. doi:139/4/244 [pii]
8. Barrett BJ, Garg AX, Goeree R, et al. A nurse-coordinated model of care versus usual care for stage 3/4 chronic kidney disease in the community: a randomized controlled trial. *Clinical journal of the American Society of Nephrology : CJASN*. Jun 2011;6(6):1241-7. doi:10.2215/CJN.07160810
9. Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. *The New England journal of medicine*. Aug 17 2017;377(7):644-657. doi:10.1056/NEJMoa1611925
10. Rosenstock J, Perkovic V, Johansen OE, et al. Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial. *JAMA*. Jan 1 2019;321(1):69-79. doi:10.1001/jama.2018.18269
11. Rosenstock J, Kahn SE, Johansen OE, et al. Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes: The CAROLINA Randomized Clinical Trial. *JAMA*. Sep 24 2019;322(12):1155-1166. doi:10.1001/jama.2019.13772
12. McMurray JJ, Ostergren J, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. *Lancet*. Sep 6 2003;362(9386):767-71. doi:10.1016/S0140-6736(03)14283-3
13. Badve SV, Pascoe EM, Tikunov A, et al. Effects of Allopurinol on the Progression of Chronic Kidney Disease. *The New England journal of medicine*. Jun 25 2020;382(26):2504-2513. doi:10.1056/NEJMoa1915833
14. Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. *The New England journal of medicine*. Jun 13 2019;380(24):2295-2306. doi:10.1056/NEJMoa1811744
15. Heerspink HJL, Stefánsson BV, Correa-Rotter R, et al. Dapagliflozin in Patients with Chronic Kidney Disease (DAPA-CKD). *The New England journal of medicine*. 2020;383(15):1436-1446. doi:10.1056/NEJMoa2024816
16. Donadio JV, Jr., Grande JP, Bergstralh EJ, Dart RA, Larson TS, Spencer DC. The long-term outcome of patients with IgA nephropathy treated with fish oil in a controlled trial. Mayo Nephrology Collaborative Group. *J Am Soc Nephrol*. Aug 1999;10(8):1772-7.
17. Donadio JV, Jr., Larson TS, Bergstralh EJ, Grande JP. A randomized trial of high-dose compared with low-dose omega-3 fatty acids in severe IgA nephropathy. *J Am Soc Nephrol*. Apr 2001;12(4):791-9.
18. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. *The New England journal of medicine*. Nov 26 2015;373(22):2117-28. doi:10.1056/NEJMoa1504720
19. White WB, Cannon CP, Heller SR, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. *The New England journal of medicine*. Oct 3 2013;369(14):1327-35. doi:10.1056/NEJMoa1305889
20. Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and Diabetic Kidney Disease. <https://ClinicalTrials.gov/show/NCT02540993>
21. Gipson DS, Trachtman H, Kaskel FJ, et al. Clinical trial of focal segmental glomerulosclerosis in children and young adults. *Kidney international*. Oct 2011;80(8):868-78. doi:10.1038/ki.2011.195
22. Goicoechea M, Garcia de Vinuesa S, Verdalles U, et al. Allopurinol and progression of CKD and cardiovascular events: long-term follow-up of a randomized clinical trial. *Am J Kidney Dis*. Apr 2015;65(4):543-9. doi:10.1053/j.ajkd.2014.11.016
23. Schrier RW, Abebe KZ, Perrone RD, et al. Blood pressure in early autosomal dominant polycystic kidney disease. *New England Journal of Medicine*. Dec 11 2014;371(24):2255-66. doi:10.1056/NEJMoa1402685
24. Torres VE, Abebe KZ, Chapman AB, et al. Angiotensin blockade in late autosomal dominant polycystic kidney disease. *New England Journal of Medicine*. Dec 11 2014;371(24):2267-76. doi:10.1056/NEJMoa1402686
25. Hannedouche T, Landais P, Goldfarb B, et al. Randomised controlled trial of enalapril and beta blockers in non-diabetic chronic renal failure. *BMJ*. Oct 1 1994;309(6958):833-7.

26. Hernandez AF, Green JB, Janmohamed S, et al. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. *Lancet*. Oct 27 2018;392(10157):1519-1529. doi:10.1016/S0140-6736(18)32261-X
27. Li PK, Leung CB, Chow KM, et al. Hong Kong study using valsartan in IgA nephropathy (HKVIN): a double-blind, randomized, placebo-controlled study. *Am J Kidney Dis*. May 2006;47(5):751-60. doi:10.1053/j.ajkd.2006.01.017
28. Hou FF, Zhang X, Zhang GH, et al. Efficacy and safety of benazepril for advanced chronic renal insufficiency. *The New England journal of medicine*. Jan 12 2006;354(2):131-40. doi:10.1056/NEJMoa053107
29. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. *The New England journal of medicine*. Sep 20 2001;345(12):851-60. doi:10.1056/NEJMoa011303
30. Ihle BU, Whitworth JA, Shahinfar S, Cnaan A, Kincaid-Smith PS, Becker GJ. Angiotensin-converting enzyme inhibition in nondiabetic progressive renal insufficiency: a controlled double-blind trial. *Am J Kidney Dis*. Apr 1996;27(4):489-95. doi:S0272-6386(96)90158-4 [pii]
31. Katafuchi R, Ikeda K, Mizumasa T, et al. Controlled, prospective trial of steroid treatment in IgA nephropathy: a limitation of low-dose prednisolone therapy. *Am J Kidney Dis*. May 2003;41(5):972-83. doi:S027263860300194X [pii]
32. Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. *The New England journal of medicine*. Jul 28 2016;375(4):311-22. doi:10.1056/NEJMoa1603827
33. Lewis EJ, Hunsicker LG, Lan SP, Rohde RD, Lachin JM. A controlled trial of plasmapheresis therapy in severe lupus nephritis. The Lupus Nephritis Collaborative Study Group. *The New England journal of medicine*. May 21 1992;326(21):1373-9.
34. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. *The New England journal of medicine*. Nov 11 1993;329(20):1456-62. doi:10.1056/NEJM199311113292004
35. Maes BD, Oyen R, Claes K, et al. Mycophenolate mofetil in IgA nephropathy: results of a 3-year prospective placebo-controlled randomized study. *Kidney international*. May 2004;65(5):1842-9. doi:10.1111/j.1523-1755.2004.00588.x
36. Maschio G, Alberti D, Janin G, et al. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. *The New England journal of medicine*. Apr 11 1996;334(15):939-45.
37. Peeters MJ, van Zuilen AD, van den Brand JA, et al. Nurse practitioner care improves renal outcome in patients with CKD. *J Am Soc Nephrol*. Feb 2014;25(2):390-8. doi:10.1681/ASN.2012121222
38. Klahr S, Levey AS, Beck GJ, et al. The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group. *The New England journal of medicine*. Mar 31 1994;330(13):877-84.
39. Imai E, Chan JC, Ito S, et al. Effects of olmesartan on renal and cardiovascular outcomes in type 2 diabetes with overt nephropathy: a multicentre, randomised, placebo-controlled study. *Diabetologia*. Dec 2011;54(12):2978-86. doi:10.1007/s00125-011-2325-z
40. McMurray JJ, Packer M, Desai AS, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. *The New England journal of medicine*. Sep 11 2014;371(11):993-1004. doi:10.1056/NEJMoa1409077
41. Bonaca MP, Braunwald E, Sabatine MS. Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction. *The New England journal of medicine*. Sep 24 2015;373(13):1274-5. doi:10.1056/NEJMc1508692
42. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. *The New England journal of medicine*. Sep 10 2009;361(11):1045-57. doi:10.1056/NEJMoa0904327
43. Ponticelli C, Zucchelli P, Passerini P, et al. A randomized trial of methylprednisolone and chlorambucil in idiopathic membranous nephropathy. *The New England journal of medicine*. Jan 5 1989;320(1):8-13.
44. Ponticelli C, Zucchelli P, Passerini P, Cesana B. Methylprednisolone plus chlorambucil as compared with methylprednisolone alone for the treatment of idiopathic membranous nephropathy. The Italian Idiopathic Membranous Nephropathy Treatment Study Group. *The New England journal of medicine*. Aug 27 1992;327(9):599-603.
45. Ponticelli C, Altieri P, Scolari F, et al. A randomized study comparing methylprednisolone plus chlorambucil versus methylprednisolone plus cyclophosphamide in idiopathic membranous nephropathy. *J Am Soc Nephrol*. Mar 1998;9(3):444-50.

46. Ponticelli C, Passerini P, Salvadori M, et al. A randomized pilot trial comparing methylprednisolone plus a cytotoxic agent versus synthetic adrenocorticotrophic hormone in idiopathic membranous nephropathy. *Am J Kidney Dis*. Feb 2006;47(2):233-40.
47. Pozzi C, Andrulli S, Del Vecchio L, et al. Corticosteroid effectiveness in IgA nephropathy: long-term results of a randomized, controlled trial. *J Am Soc Nephrol*. Jan 2004;15(1):157-63.
48. Pozzi C, Andrulli S, Pani A, et al. Addition of azathioprine to corticosteroids does not benefit patients with IgA nephropathy. *J Am Soc Nephrol*. Oct 2010;21(10):1783-90. doi:10.1681/ASN.2010010117
49. Pozzi C, Andrulli S, Pani A, et al. IgA nephropathy with severe chronic renal failure: a randomized controlled trial of corticosteroids and azathioprine. *Journal of nephrology*. Jan-Feb 2013;26(1):86-93. doi:10.5301/jn.5000110
50. Praga M, Gutierrez E, Gonzalez E, Morales E, Hernandez E. Treatment of IgA nephropathy with ACE inhibitors: a randomized and controlled trial. *J Am Soc Nephrol*. Jun 2003;14(6):1578-83.
51. Ruggenti P, Perna A, Gherardi G, et al. Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. *Lancet*. Jul 31 1999;354(9176):359-64.
52. Ruggenti P, Perna A, Loriga G, et al. Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): multicentre, randomised controlled trial. *Lancet*. Mar 12-18 2005;365(9463):939-46.
53. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. *The New England journal of medicine*. Sep 20 2001;345(12):861-9.
54. Hou FF, Xie D, Zhang X, et al. Renoprotection of Optimal Antiproteinuric Doses (ROAD) Study: a randomized controlled study of benazepril and losartan in chronic renal insufficiency. *J Am Soc Nephrol*. Jun 2007;18(6):1889-98. doi:ASN.2006121372 [pii]

10.1681/ASN.2006121372
55. Manno C, Torres DD, Rossini M, Pesce F, Schena FP. Randomized controlled clinical trial of corticosteroids plus ACE-inhibitors with long-term follow-up in proteinuric IgA nephropathy. *Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association*. Dec 2009;24(12):3694-701. doi:10.1093/ndt/gfp356
56. Baigent C, Landray MJ, Reith C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. *Lancet*. Jun 25 2011;377(9784):2181-92. doi:10.1016/S0140-6736(11)60739-3
57. Heerspink HJL, Parving HH, Andress DL, et al. Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial. *Lancet*. May 11 2019;393(10184):1937-1947. doi:10.1016/S0140-6736(19)30772-X
58. Sprint Research Group, Wright JT, Jr., Williamson JD, et al. A Randomized Trial of Intensive versus Standard Blood-Pressure Control. *The New England journal of medicine*. Nov 26 2015;373(22):2103-16. doi:10.1056/NEJMoa1511939
59. Rauen T, Eitner F, Fitzner C, et al. Intensive Supportive Care plus Immunosuppression in IgA Nephropathy. *New England Journal of Medicine*. 2015;373(23):2225-2236. doi:doi:10.1056/NEJMoa1415463
60. Packham DK, Wolfe R, Reutens AT, et al. Sulodexide fails to demonstrate renoprotection in overt type 2 diabetic nephropathy. *J Am Soc Nephrol*. Jan 2012;23(1):123-30. doi:10.1681/ASN.2011040378
61. Pitt B, Pfeffer MA, Assmann SF, et al. Spironolactone for heart failure with preserved ejection fraction. *The New England journal of medicine*. Apr 10 2014;370(15):1383-92. doi:10.1056/NEJMoa1313731
62. van Essen GG, Apperloo AJ, Rensma PL, et al. Are angiotensin converting enzyme inhibitors superior to beta blockers in retarding progressive renal function decline? *Kidney Int Suppl*. Dec 1997;63:S58-62.
63. Zucchelli P, Zuccala A, Borghi M, et al. Long-term comparison between captopril and nifedipine in the progression of renal insufficiency. *Kidney international*. Aug 1992;42(2):452-8.